摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-ethenylpiperazine | 45588-89-4

中文名称
——
中文别名
——
英文名称
3-ethenylpiperazine
英文别名
2-Ethenylpiperazine
3-ethenylpiperazine化学式
CAS
45588-89-4
化学式
C6H12N2
mdl
MFCD19226507
分子量
112.175
InChiKey
YFVRIXYUQCYRAF-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    183.2±25.0 °C(Predicted)
  • 密度:
    0.939±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    -0.2
  • 重原子数:
    8
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.666
  • 拓扑面积:
    24.1
  • 氢给体数:
    2
  • 氢受体数:
    2

反应信息

  • 作为反应物:
    描述:
    3-ethenylpiperazine7-氯-6-氟-1-环丙基-1,4-二氢-4-氧-3-喹啉羧酸吡啶 为溶剂, 反应 18.0h, 以giving 210 mg of the desired product的产率得到1-cyclopropyl-7-(3-ethenyl-1-piperazinyl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
    参考文献:
    名称:
    7-(substituted)piperaziny
    摘要:
    7-(取代)piperazinyl-1-乙基-6-氟-4-氧代-3-喹啉羧酸及其药理学上可接受的盐,包含它们的组合物,用于生产它们的过程和中间体,以及使用它们治疗温血动物细菌感染的方法。
    公开号:
    US04940710A1
点击查看最新优质反应信息

文献信息

  • N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES
    申请人:GRIFFIOEN Gerard
    公开号:US20100197703A1
    公开(公告)日:2010-08-05
    This invention provides thiazolylpiperazine derivatives, and N-sulfonyl heterocyclic derivatives including phenyl- and benzyl-thiazolylpiperidine derivatives, and pharmaceutically acceptable salts thereof, which are useful active ingredients for administration in a method for the treatment of an α-synucleopathy such as Parkinson's disease, diffuse Lewy body disease, traumatic brain injury, amyotrophic lateral sclerosis, Niemann-Pick disease, Hallervorden-Spatz syndrome, Down syndrome, neuroaxonal dystrophy, multiple system atrophy and Alzheimer's disease. This invention also provides methods for making such derivatives, and pharmaceutical compositions including such derivatives together with pharmaceutically acceptable excipients.
    该发明提供了噻唑哌嗪生物,以及包括苯基和苄基噻唑哌啶生物的N-磺酰杂环衍生物,以及其药学上可接受的盐,这些是用于治疗α-突触核蛋白病的有效活性成分,如帕森病、弥漫性小体病、创伤性脑损伤、肌萎缩侧索硬化症、尼曼-匹克病、哈勒沃登-施帕茨综合征、唐氏综合征、神经轴突萎缩、多系统萎缩和阿尔茨海默病的治疗方法。该发明还提供了制备这些衍生物的方法,以及包括这些衍生物和药学上可接受的辅料的药物组合物。
  • Piperazine derivatives
    申请人:American Cyanamid Company
    公开号:US05210193A1
    公开(公告)日:1993-05-11
    7-(substituted)piperazinyl-1-ethyl-6-fluoro-4-oxo-3-quinolinecarboxylic acids, the pharmacologically acceptable salts thereof, compositions containing them, processes and intermediates for producing them, and methods of using them to treat bacterial infections in warm-blooded animals.
    7-(取代)piperazinyl-1-乙基-6--4-氧代-3-喹啉羧酸及其药理学上可接受的盐,含有它们的组合物,生产它们的过程和中间体以及使用它们治疗温血动物细菌感染的方法。
  • [EN] FUSED-RING HETEROCYCLE DERIVATIVE AND MEDICAL APPLICATION THEREOF<br/>[FR] DÉRIVÉ HÉTÉROCYCLIQUE À CYCLES FUSIONNÉS ET SON APPLICATION MÉDICALE<br/>[ZH] 一种并环杂环衍生物及其在医药上的应用
    申请人:SICHUAN HAISCO PHARMACEUTICAL CO LTD
    公开号:WO2022223022A1
    公开(公告)日:2022-10-27
    提供一种通式(I)所述的化合物或者其立体异构体、代物、溶剂化物、前药、代谢产物、药学上可接受的盐或共晶,及其中间体和制备方法,以及在制备治疗与PAR P7活性或表达量相关疾病的药物中的应用。
  • 7-(Substituted)piperazinyl-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids
    申请人:AMERICAN CYANAMID COMPANY
    公开号:EP0230053A2
    公开(公告)日:1987-07-29
    7-(substituted)piperazinyl-1-ethyl-6-fluoro-4-oxo-3-quinolinecarboxylic acids, the pharmacologically acceptable salts thereof, compositions containing them, processes and intermediates for producing them, and methods of using them to treat bacterial infections in warm-blooded animals.
    7-(取代)哌嗪基-1-乙基-6--4-氧代-3-喹啉羧酸、其药理上可接受的盐、含有它们的组合物、生产它们的工艺和中间体,以及用它们治疗温血动物细菌感染的方法。
  • RESIN COMPOSITION FOR OPTICAL MOLDING
    申请人:Kuraray Noritake Dental Inc.
    公开号:EP3900693A1
    公开(公告)日:2021-10-27
    The present invention provides a resin composition for optical shaping that emits a weaker odor, enables easy fabrication of an object by virtue of its low viscosity, and can be made into a fabricated product having desirable toughness and water resistance when used for stereolithographic fabrication (particularly by vat stereolithography) and that is particularly suited for dental occlusal splints, mouth guards, and denture base materials. The present invention relates to a resin composition for optical shaping comprising: an α,β-unsaturated double bond group-containing compound (A) having a ring structure (a) containing a nitrogen atom; a (meth)acrylic acid ester compound (B) having a boiling point of 280°C or more at normal pressure, having a carbocyclic group, and having no nitrogen-containing heterocyclic group; a photopolymerization initiator (C); and optionally, a polyfunctional polymerizable monomer (E) having a molecular weight of 500 or less and not comprised in the α,β-unsaturated double bond group-containing compound (A) and the (meth)acrylic acid ester compound (B), wherein the content of the polyfunctional polymerizable monomer (E) having a molecular weight of 500 or less is 20 mass% or less relative to the total amount of polymerizable compounds comprised in the resin composition for optical shaping.
    本发明提供了一种用于光学整形的树脂组合物,该组合物散发的气味较弱,因其粘度低而易于制造物体,在用于立体光刻制造(特别是大桶立体光刻)时,可制成具有理想韧性和耐性的制成品,特别适用于牙科咬合夹板、护齿板和义齿基底材料。本发明涉及一种用于光学塑形的树脂组合物,包括具有含氮原子的环结构 (a) 的含 α、β-不饱和双键基团的化合物 (A);(甲基) 丙烯酸酯化合物 (B),在常压下的沸点为 280°C 或更高,具有碳环基团,且不含含氮杂环基团;光聚合引发剂 (C);以及可选的分子量为 500 或以下且不包含在含α,β-不饱和双键基团的化合物(A)和(甲基)丙烯酸酯化合物(B)中的多功能可聚合单体(E),其中分子量为 500 或以下的多功能可聚合单体(E)的含量占光学成型用树脂组合物中可聚合化合物总量的 20% 或以下。
查看更多